NCT04815369

Brief Summary

This prospective, multicenter, comparative cohort observational study is to determine whether the use of Guidance® UTI Clinical Pathway, a standardized infrastructure for specimen collection and result delivery, compared with current traditional pathways for urine testing reduces the proportion of UTI patients with poor outcomes.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Jun 2021

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 22, 2021

Completed
3 days until next milestone

First Posted

Study publicly available on registry

March 25, 2021

Completed
2 months until next milestone

Study Start

First participant enrolled

June 7, 2021

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 30, 2024

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 8, 2024

Completed
Last Updated

May 28, 2025

Status Verified

November 1, 2024

Enrollment Period

3 years

First QC Date

March 22, 2021

Last Update Submit

May 27, 2025

Conditions

Keywords

Nursing HomeClostridium difficilePCRLong Term Care FacilitySkilled Nursing FacilityNational Healthcare Safety Network

Outcome Measures

Primary Outcomes (1)

  • Examine prospective data to determine if the use of Guidance® UTI Clinical Pathway, compared to traditional clinical pathways, will reduce the proportion of patients with UTI-related adverse events.

    Examine the proportion of patients with UTI-related adverse events requiring emergency hospital services over the course the study with a composite measure of the number of UTI related ED visits and/or subsequent hospitalizations and/or sepsis events.

    12 Months

Secondary Outcomes (3)

  • Examine prospective data to determine if the use of Guidance® UTI Clinical Pathway, compared to traditional clinical pathways, will reduce overall inappropriate antibiotic use.

    30 Days

  • Examine prospective data to determine if the use of Guidance® UTI Clinical Pathway is more effective than standard urine testing approaches in the clinical evaluation of UTI diagnosis and management .

    12 Months

  • Examine prospective data to determine if the use of Guidance® UTI Clinical Pathway, compared to traditional clinical pathways, will reduce UTI antibiotic collateral effects.

    30 Days

Study Arms (2)

Guidance Clinical Pathway

Facilities will be provided a standardized infrastructure and process for collecting and reporting of urine test results including unique lab requisitions that contain the option to order Guidance® UTI, Standard Urine Culture (SUC), and Urine Analysis (UA) along with a protocol for results notification to a central point person within the Nursing Home (NH) facility

Traditional Clinical Pathway

Facilities will employ their current standard clinical care practices for suspected UTI, including SUC, UA, and Guidance® UTI testing as per current reporting practices. Providers at these facilities will have the option to order any diagnostic test they deem appropriate.

Eligibility Criteria

Age65 Years+
Sexall
Healthy VolunteersYes
Age GroupsOlder Adult (65+)
Sampling MethodProbability Sample
Study Population

Cohort of residents residing in the NH facility during 12 consecutive months.-

You may qualify if:

  • Certified skilled nursing facilities (SNF) and nursing homes (NH)
  • Nonprofit or for-profit freestanding facility certified by Medicare and Medicaid
  • Currently utilizing an EMR system
  • Minimum bed size of 100

You may not qualify if:

  • Assisted Living Facilities and Residential Care Facilities
  • Participation in another UTI trial during the study period

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Pathnostics

Irvine, California, 92614, United States

Location

MeSH Terms

Conditions

Urinary Tract Infections

Condition Hierarchy (Ancestors)

InfectionsUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital Diseases

Study Officials

  • Dave Baunoch, PhD

    Clinical Trials

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 22, 2021

First Posted

March 25, 2021

Study Start

June 7, 2021

Primary Completion

May 30, 2024

Study Completion

November 8, 2024

Last Updated

May 28, 2025

Record last verified: 2024-11

Data Sharing

IPD Sharing
Will not share

Locations